March 2024 Quarterly Activities Report
Highlights
Design transfer activities completed, with reliable and reproducible data supporting progression to prototype manufacture
Publication of second peer-reviewed dataset confirms substantial performance advantage over current standard of care testing using CA125
CLEO’s strategic U.S. market access and reimbursement program underway with appointment of New York-based industry partner HcFocus
U.S. clinical trial established, with U.S.-based Lindus Health managing site logistics and patient recruitment
Physician engagement commenced in Australia
A$9.973M cash at bank at 31 March 2024.